BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
Excerpt from the Press Release:
SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones as a part of the collaboration. BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development and commercialization. The companies did not disclose financial terms.
In the collaboration, Deep Genomics will use its AI Workbench to identify and validate target mechanisms and lead candidates, and BioMarin will advance them into preclinical and clinical development. The AI Workbench enables rapid exploration of novel targetable mechanisms and therapeutic candidates. It combines deep learning, automation, advanced biomedical knowledge and massive amounts of in vitro and in vivo data to accurately identify targetable molecular mechanisms and guide the discovery and development of oligonucleotide therapies.
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?